Product Images Levetiracetam
View Photos of Packaging, Labels & Appearance
Product Label Images
The following 8 images provide visual information about the product associated with Levetiracetam NDC 71093-144 by Aci Healthcare Usa, Inc., such as packaging, labeling, and the appearance of the drug itself. This resource could be helpful for medical professionals, pharmacists, and patients seeking to verify medication information and ensure they have the correct product.
image-01 - image 01
image-02 - levetiracetam fig1
image-01 - levetiracetam fig2
The text describes Figure 2 showing the Responder Rate in Study 2 with a comparison of placebo versus two different dosages of Levetiracetam. The figure shows the percentage of patients who had a 250% reduction from baseline. One dosage of Levetiracetam resulted in a statistically significant difference from placebo.*
image-03 - levetiracetam fig3
The Figure 3 shows the Responder Rate, with more than 50% of reduction from baseline in Study 3. The percentage of responder rate for placebo (N=104) was 14.4%, whereas for Levetiracetam 3000 mg/day (N=180) was 45%, and it's statistically significant versus placebo. There is a graphical representation of data with bars and percentages.*
image-04 - levetiracetam fig4
The figure shows the Responder Rate in Study 4 with a 50% Reduction from Baseline. The placebo group had a Responder Rate of 19.6% while the group using Levetiracetam had a Responder Rate of 44.6%. The data indicates that the Levetiracetam group had a statistically significant improvement in Responder Rate compared to the placebo group.*
image-05 - levetiracetam fig5
The text describes Figure 5 which shows the Responder Rate for all patients aged 1 month to less than 4 years, and their reduction from baseline in Study 5. The figure displays a bar graph that compares the percentage of patients who responded to treatment after being given Placebo and Levetiracetam. The graph shows that Levetiracetam had a statistically significant higher responder rate compared to Placebo.*
image-06 - levetiracetam fig6
The figure shows the responder rate in PGTC seizure frequency per week in Study 7 with a 250% reduction from baseline. The percentage of patients who responded to the treatment is shown on the y-axis while the treatment groups (placebo and levetiracetam) are shown on the x-axis. The results indicate that 72.2% of patients in the levetiracetam group had a significant reduction in PGTC seizure frequency, which was statistically significant compared to the placebo group. 45.2% of patients in the placebo group had a reduction in seizure frequency. 9% of patients did not respond to the treatment.*
image-8 - levetiracetam label
Levetiracetam is a medication available in the form of an oral solution in the United States Pharmacopeia (USP). Further details about the medication are not available.*
* The product label images have been analyzed using a combination of traditional computing and machine learning techniques. It should be noted that the descriptions provided may not be entirely accurate as they are experimental in nature. Use the information in this page at your own discretion and risk.